Dr. Marinna Madrid is Co-Founder of Cellino, an early-stage biotechnology company seeking to make personalized, autologous cell therapies viable at large scale for the first time. Cellino’s platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format, enabling thousands of patient samples to be processed in parallel in a single facility.